Sara Poston

ORCID: 0000-0003-4735-057X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Herpesvirus Infections and Treatments
  • Vaccine Coverage and Hesitancy
  • Acne and Rosacea Treatments and Effects
  • Cytomegalovirus and herpesvirus research
  • Influenza Virus Research Studies
  • Bone health and treatments
  • Hepatitis Viruses Studies and Epidemiology
  • Respiratory viral infections research
  • Health Systems, Economic Evaluations, Quality of Life
  • Cardiac, Anesthesia and Surgical Outcomes
  • Enhanced Recovery After Surgery
  • Bone health and osteoporosis research
  • Pneumonia and Respiratory Infections
  • Bone and Joint Diseases
  • Bacterial Infections and Vaccines
  • Viral gastroenteritis research and epidemiology
  • COVID-19 epidemiological studies
  • Urticaria and Related Conditions
  • Hepatitis B Virus Studies
  • Bartonella species infections research
  • Rabies epidemiology and control
  • Vector-borne infectious diseases
  • Advanced Breast Cancer Therapies
  • Prostate Cancer Diagnosis and Treatment
  • Breast Cancer Treatment Studies

GlaxoSmithKline (United States)
2009-2025

Triangle
2020-2024

Outcomes Research Consortium
2024

Children's Hospital of Pittsburgh
2023

GlaxoSmithKline (Belgium)
2021

University of Cincinnati
2021

Scientific Technologies Corporation (United States)
2021

NRG Oncology
2021

RTI Health Solutions
2019-2020

Optum (United States)
2016

Respiratory syncytial virus (RSV) is an important cause of lower respiratory tract disease in older adults, resulting substantial morbidity and mortality.

10.1007/s40121-024-00939-w article EN cc-by-nc Infectious Diseases and Therapy 2024-03-20

Respiratory syncytial virus (RSV) is associated with considerable morbidity and mortality among older adults (aged ≥60 years) certain chronic conditions in the United States (US). Despite this burden, no previous studies have assessed knowledge, attitudes, perceptions (KAP) of RSV these populations. This study evaluates RSV-related KAP US at increased risk severe infection. A cross-sectional, web-based survey was administered from May to June 2022 better understand respiratory infection- who...

10.1080/21645515.2024.2303796 article EN cc-by-nc Human Vaccines & Immunotherapeutics 2024-01-31

The economic effect of the use alvimopan in four randomized, double-blind, placebo-controlled, Phase III, North American efficacy trials was analyzed.Patients were eligible for study if they 18 years or older, undergoing laparotomy partial small large bowel resection with primary anastomosis, and scheduled postoperative pain management opioid-based i.v. patient-controlled analgesia. Patients analyzed III received placebo 12 mg orally before surgery. Doses administered twice daily beginning...

10.2146/ajhp080329 article EN American Journal of Health-System Pharmacy 2009-07-27

In Brief Objective: To evaluate in-hospital clinical outcomes after open and laparoscopic bowel resection (BR) with or without alvimopan treatment. Background: Delayed return of gastrointestinal function BR may be associated greater postoperative morbidity increased hospital length stay (LOS). trials, alvimopan—a peripherally acting μ-opioid receptor antagonist—accelerated recovery BR. Methods: A retrospective matched-cohort study (NCT01150760) was conducted using a national inpatient...

10.1097/sla.0b013e31824a36cc article EN Annals of Surgery 2012-03-04

Despite vaccination recommendations, the burden of vaccine-preventable diseases remains high in older adults United States (US), contributing to substantial morbidity, mortality, and health care resource use costs. To adequately plan for needs help inform policies, disease projections that account population aging over coming decades are needed. As a first step, this exploratory study projects influenza, pertussis, herpes zoster, pneumococcal aged 50 y US, using population-based modeling...

10.1080/21645515.2020.1780847 article EN cc-by Human Vaccines & Immunotherapeutics 2020-08-06

Objective To estimate the incidence of herpes zoster (HZ) in patients with rheumatoid arthritis (RA) compared general population USA. Methods This retrospective, longitudinal cohort study used data from an administrative claims database containing both commercial and Medicare Advantage Part D data, a period October 2015 to February 2020. Patients were aged ≥ 18 years divided into 2 cohorts: RA without RA. Diagnosis procedure codes identify HZ cases calculate rates (IRs) cohorts. Data...

10.3899/jrheum.220986 article EN The Journal of Rheumatology 2023-02-01

Individuals who are immunocompromised (IC) due to therapy or underlying disease at increased risk of herpes zoster (HZ). This study evaluates the public health impact recombinant vaccine (RZV) relative no HZ vaccination for prevention among adults aged ≥18 years diagnosed with selected cancers in United States (US). A static Markov model was used simulate three cohorts individuals IC cancer (time horizon 30 years; one-year cycle length): hematopoietic stem cell transplant (HSCT) recipients,...

10.1080/21645515.2023.2167907 article EN cc-by-nc-nd Human Vaccines & Immunotherapeutics 2023-01-02

Early provisions of the Affordable Care Act (ACA) reduced financial barriers to preventive care, including routinely recommended vaccines; however, vaccination coverage remains suboptimal. This study examined characteristics routine adult vaccinations and potential missed opportunities for through lens healthcare resource utilization among adults in ACA era.This was a retrospective analysis claims from Truven Health MarketScan Commercial Claims Encounters (CCAE), Medicare Supplemental (MS),...

10.1016/j.vaccine.2020.02.057 article EN cc-by Vaccine 2020-02-27

Recombinant zoster vaccine has been recommended by the US Advisory Committee on Immunization Practices (ACIP) for prevention of herpes (HZ) in immunocompetent adults aged at least 50 years since 2018. In January 2022, this was extended to immunodeficient/immunosuppressed 19 years. Key study objectives were assess specialists' knowledge ACIP HZ vaccination recommendations, their attitudes toward vaccination, and practices/barriers. This cross-sectional, web-based survey (conducted March 2022)...

10.1089/pop.2023.0284 article EN Population Health Management 2024-06-05

Overexpression of the human epidermal growth factor receptor 2 (HER2) protein negatively affects survival in breast cancer. This study aimed to assess real-world treatment patterns and costs associated with resected nonmetastatic HER2-positive cancer United States.Commercially insured patients were identified from oncology registry data linked a large US commercial administrative claims database. Treatment health care use initial phase examined.Among 915 who met criteria, 662 (72%) hormone...

10.1200/jop.2015.004747 article EN Journal of Oncology Practice 2016-02-01

This exploratory study estimates the economic value of current vaccination program and increased coverage against four preventable diseases in older adults United States (US). A population-based, age-structured model was used to conduct a cost-benefit analysis influenza, pertussis, herpes zoster, pneumococcal disease among US aged 50 years older, accounting for aging population. The separate decision trees each project discounted number vaccinated individuals, cases, direct medical indirect...

10.1016/j.vaccine.2021.07.029 article EN cc-by Vaccine 2021-07-30

Research has shown a high prevalence of potentially inappropriate medication prescribing (PIP) for elderly patients in outpatient settings, but little is known about whether physician's practice setting influences attitudes. This study examines the PIP among 2 out-patient practices, 1 located senior citizens center and general family medicine clinic. The authors conducted retrospective chart review random sample 50 individuals aged 65 years or older from each practice. 2003 version Beers...

10.1177/1062860605285475 article EN American Journal of Medical Quality 2006-05-01

Serogroup B meningococcal (MenB) vaccination recommendations for adolescents in the United States (US) include routine all individuals at increased risk and not aged 16-23 years (preferred age 16-18 years) based on shared clinical decision-making. The two licensed MenB vaccines require administration of ≥2 doses.This cross-sectional study analyzed 2017-2018 National Immunization Survey-Teen (NIS-Teen) data to evaluate ≥1 dose coverage among 17 years. Multivariable logistic regression was...

10.1016/j.vaccine.2021.03.071 article EN cc-by Vaccine 2021-04-13

To estimate the incremental healthcare resource utilization (HRU) and cost burden posed by herpes zoster (HZ) in adult patients with rheumatoid arthritis (RA) United States.A retrospective cohort study was conducted using an administrative claims database containing commercial Medicare Advantage Part D data, between October 2015 February 2020. Patients RA HZ (RA+/HZ+) or without (RA+/HZ-) were identified based on diagnosis codes relevant medications. Outcomes measured included HRU medical,...

10.1007/s40744-023-00549-x article EN cc-by-nc Rheumatology and Therapy 2023-05-23

Patients with psoriasis (PsO) are at increased risk of herpes zoster (HZ), but recent data on the incidence HZ among patients PsO and impact healthcare resource use (HRU) costs for have not been described. This retrospective, longitudinal, cohort study estimated in cohorts adults vs without (PsO + PsO-) HRU those PsO, /HZ /HZ-) using Optum's de-identified Clinformatics Data Mart Database during 2015-2020. psoriatic arthritis were excluded from all four cohorts. Comparisons between used...

10.1007/s13555-023-00988-y article EN cc-by-nc Dermatology and Therapy 2023-09-22

Respiratory syncytial virus (RSV) is a common cause of acute respiratory illness in individuals all ages, with adults aged ≥60 years and certain chronic conditions at increased risk severe RSV-related outcomes. This study evaluates the cost-effectiveness adjuvanted RSVPreF3 vaccine versus no United States (US). A multi-cohort Markov model was developed 5-year time horizon 1-month cycle length to compare outcomes for vaccination one-time (assuming same as influenza vaccines). Clinical...

10.1080/21645515.2024.2432745 article EN cc-by-nc Human Vaccines & Immunotherapeutics 2024-12-09

Adult immunization rates in the United States remain low. More convenient access to information systems (IIS) may improve vaccination rates.The objective of this multilevel, clustered, randomized controlled study was measure impact providing pharmacists with software and training query IIS for patient vaccine history/recommendations on adult influenza, pneumococcal, herpes zoster, Td/Tdap rates.California Rite Aid pharmacy districts were into intervention/control groups using stratified...

10.1016/j.japh.2021.09.010 article EN cc-by Journal of the American Pharmacists Association 2021-09-29

A 48‐year‐old woman with a questionable history of an unspecified ceftriaxone allergy was treated cefazolin for surgical antibiotic prophylaxis. After she tolerated therapy 4 days, the medical staff concluded that her inaccurate, and intravenous suspected nosocomial pneumonia. Approximately 10 minutes after start infusion, patient experienced anaphylaxis. Initial symptoms oral angioedema laryngopharyngeal constriction progressed to dyspnea, tachypnea, hypotension, tachycardia, all which...

10.1592/phco.24.6.668.34753 article EN Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy 2004-05-01

Patients with inflammatory bowel disease (IBD) are at increased risk of herpes zoster (HZ). We evaluated the incidence HZ in ulcerative colitis (UC) and Crohn's (CD) patients compared this a non-IBD population.We conducted retrospective cohort study (GSK identifier: VEO-000043) adults aged ≥18 years UC CD without IBD who were identified from claims recorded US healthcare database between October 2015 February 2020. Crude rates/1,000 person-years (PY) calculated, comparisons rates or cohorts...

10.1093/gastro/goad016 article EN cc-by Gastroenterology report 2022-12-30

Due to COVID-19, vaccinations dropped in 2020 and 2021. We estimated the impact of reduced recombinant zoster vaccine (RZV) use on herpes (HZ) cases, complications, quality-adjusted life-year (QALY) losses among older adults. Various scenarios were compared with Markov models using data from national sources, clinical trials, literature. Missed series initiations calculated based RZV distributed doses. In 2020, 3.9 million missed, resulting 31,945 HZ 2,714 postherpetic neuralgia 610 lost...

10.1080/21645515.2022.2027196 article EN cc-by-nc-nd Human Vaccines & Immunotherapeutics 2022-01-20
Coming Soon ...